Skip to main content

Table 1 Baseline clinical characteristics in the whole group of patients

From: Dosimetric and clinical analysis of pseudo-progression versus recurrence after hypo-fractionated radiotherapy for brain metastases

Characteristic

N (%)

The median age, range (yrs)

56, 30–83

Gender

 Male

53 (43.1)

 Female

70 (56.9)

Primary tumor

 NSCLC

73 (59.3)

 SCLC

20 (16.3)

 BC

22 (17.9)

 Others

8 (6.5)

Gene mutation

 EGFR

47 (38.2)

 ALK

8 (6.5)

 Her-2

11 (8.9)

 BRCA

1 (0.8)

 None of above listed

56 (45.5)

BM location

 Cerebrum

93 (75.6)

 Cerebellum

29 (23.6)

 Brainstem

1 (0.8)

KPS

  ≥ 80

94 (76.4)

  < 80

29 (23.6)

BM volume

  ≥ 6 cc

72 (58.5)

  < 6 cc

51 (41.5)

RT regimens

 PCI or previous WBRT

33 (26.8)

 HFRT alone

69 (56.1)

 SRS concurrent with WBRT

21 (17.1)

Systemic treatments

 Chemotherapy

57 (46.3)

 TMZ

56 (45.5)

 Targeted therapy

61 (49.6)

 Immunotherapy

7 (5.7)

  1. N number, BM brain metastases, EGFR epidermal growth factor receptor, ALK anaplastic lymphoma kinase, Her-2 Human epidermal growth factor receptor-2, BRCA Breast cancer susceptibility gene, KPS Karnofsky Performance Score, RT radiation therapy, SRS stereotactic radiosurgery, TMZ Temozolomide